logo

HROW

Harrow·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --

HROW fundamentals

Harrow (HROW) released its earnings on Nov 10, 2025: revenue was 71.60M (YoY +45.36%), missed estimates; EPS was 0.33 (YoY +375.00%), beat estimates.
Revenue / YoY
71.60M
+45.36%
EPS / YoY
0.33
+375.00%
Report date
Nov 10, 2025
HROW Earnings Call Summary for Q3,2025
  • Revenue Growth: Q3 2025 revenue up 45% YoY to $71.6M, driven by VEVYE (22% QoQ) and IHEEZO (20% QoQ)
  • VEVYE Momentum: 36% increase in prescribing physicians, $22.6M Q3 revenue, 2026 PBM coverage win
  • TRIESENCE Expansion: 67% QoQ growth, 53% new accounts, launched in ocular inflammation
  • Strategic Acquisitions: Melt Pharmaceuticals acquisition adds MELT-300 for non-opioid cataract surgery
  • Financial Guidance: Full year 2025 revenue $270-280M, EBITDA $22.7M, operating leverage improving
EPS
Revenue

Revenue & Expenses

HROW has released its 2025 Q3 earnings report, with revenue of 71.64M, reflecting a YoY change of 45.44%, and net profit of 1.02M, showing a YoY change of 124.17%. The Sankey diagram below clearly presents HROW's revenue sources and cost distribution.

Key Indicators

Harrow (HROW) key financial stats and ratios, covering profitability, financial health, and leverage.
Harrow (HROW)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Harrow (HROW)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Harrow (HROW)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does Harrow (HROW) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track Harrow (HROW) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield